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Innovations
ZymoGenetics
A Quiet Powerhouse Emerges
portion of the expense in the drug E. coli. The relationship grew, and
ZymoGenetics was soon absorbeddiscovery process comes relatively
late in the development pipeline— as the U.S. R&D arm of Novo Nordisk
Drug Discovery: For most, the ex-
pression conjures up thoughts of big
pharma and the hunt for “small-mol-
ecule drugs” to treat cancer and during clinical trials. A major reason in 1988, providing the former with a
much-needed infusion of cash.other human diseases. And rightly for drug failure is unforeseen toxici-
ties or poor bioavailability. However,so; this is big business that contin- Retaining both their name and a
significant degree of independence,ues to produce important drugs with most therapeutic proteins occur nat-
urally in the human body, makinghuge implications for human health ZymoGenetics benefited greatly from
the financial security that Novoand society—think Gleevec, Prozac, them less likely to trigger adverse
effects. Another key advantage isLipitor, or Allegra. Although the provided. Largely buffeted from the
commercial pressures weighing upontechnologies of this type of drug dis- that it is difficult to create a “generic
version” of a protein. “The Holy Grailcovery have become much more so- other genomics companies in the
90s, they were able to nurture a top-phisticated since aspirin hit the mar- of the pharma industry is exclusiv-
ity,” explains ZymoGenetics Presi-ket more than 100 years ago, the notch bioinformatics group that built
upon the company’s base in proteinmodus operandi remains relatively dent and CEO Bruce L.A. Carter,
“and proteins provide a better op-unchanged. Screen a series of syn- biochemistry. They created and
honed computational strategies tothetic or natural molecules for inter- portunity to achieve this than small-
molecule drugs.”action with a drug target (usually a query genomic databases, allowing
them to focus on the relatively smallprotein) that plays a pivotal role in a
biochemical pathway involved in the fraction of human genes with an ar-
guably greater potential for thera-molecular pathogenesis of human “A small number of pro-disease. The ultimate prize at the peutic exploitation—for example,
tein families are providingend of this costly and painstaking growth factors or cytokines. The logic
was to probe databases with so-process is a drug lead that modifies the most valuable intel-
the activity of the protein in the body phisticated, proprietary digital rep-lectual property comingto treat or prevent the disease—and resentations of key protein motifs
out of genomics today”significant revenues for the com- and structure prediction algorithms
to look for putative proteins similarpany if the market for the drug is –Patrick O’Hara, Vice
sufficiently large. to those that had already provenPresident of Bioinfor-However, the availability today of themselves in the market. Armed
matics.the catalog of known and putative with these tools, the company has
human proteins in the form of the zeroed in on hundreds of genes
genome—coupled with powerful new rather than the thousands in the
This approach may be relativelybioinformatics tools—has given rise sights of its competitors. “A small
new, but ZymoGenetics is no “newto an additional paradigm in drug number of protein families are pro-
kid on the block.” Founded morediscovery. This fundamentally differ- viding the most valuable intellectual
than 20 years ago by Earl Davie andent strategy, sometimes called the property coming out of genomics to-
Benjamin Hall of the University of“gene first” approach, is one on day,” explains Patrick O’Hara, Vice
Washington and the late Nobel lau-which a Seattle-based biotechnol- President of Bioinformatics.
reate Michael Smith of the Universityogy company called ZymoGenetics And intellectual property they
of British Columbia, ZymoGenetics’has bet its future. Rather than creat- have. After a private placement of-
early focus was on the developmenting and screening new chemical fering of $150 million, ZymoGenetics
of production systems for recombi-entities, ZymoGenetics plans to har- was reestablished as an indepen-
nant proteins. “The original impetusness the therapeutic potential that dent company in November 2000
behind the foundation of ZymoGe-exists inherently in specific catego- and currently holds more than 225
netics was the desire to commercial-ries of human protein. “Proteins as issued U.S. patents. Such a portfolio
ize our yeast protein production sys-drugs” is a therapeutic modality that puts the company in the same
tem,” explains Hall. Their expertiseis complementary to the action of league as better-known competitors
in the area led to a collaboration withsmall-molecule inhibitors. Protein Human Genome Sciences and Gen-
Denmark’s pharmaceutical giant,therapeutics generally involves a entech. Under a collaborative licens-
ing agreement in effect over the nextgain-of-function effect rather than Novo Nordisk A/S, which was look-
ing for a partner to produce its ownthe inhibition of a key enzyme. four years, Novo retains options to
license up to eight proteins resultingA focus on proteins as therapeu- version of recombinant insulin to
compete with the Eli Lilly-Genen-tics also provides important advan- from discoveries made at ZymoGen-
etics. According to this agreement,tages on the business side. A hefty tech Humulin protein, produced in
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ZymoGenetics retains exclusive get, they raised another $110 million, With a solid research and discovery
record, a rich horde of IP, and a sea-rights to the proteins for North Amer- providing needed cash as they move
their products toward the clinic.ica, whereas Novo may obtain a li- soned management team, the com-
pany is well placed to make goodcense in the rest of the world. Be- The first two candidates that Zy-
moGenetics is advancing towardcause ZymoGenetics intends to on its aggressive goal of being a
leader in protein therapeutics. Bigfocus its development and market- clinical studies are recombinant hu-
man (rh) Factor XIII and rh Thrombin.ing activities in North America, the pharma? Not quite yet, but Zymo-
Genetics has quietly laid the ground-agreement gives ZymoGenetics a These two molecules, which are key
proteins in the blood coagulationcrucial and seasoned product devel- work to aim for their ranks.
opment, production, and marketing cascade, are being developed to
Robert M. Frederickson is a freelance bio-partner outside North America. “This treat bleeding complications associ-
tech writer based in Seattle (rfreder@yahoo.agreement provides ZymoGenetics ated with surgery. ZymoGenetics in-
com).
a built-in partnership with one of the tends to file investigational new drug
world’s largest manufactures of re- applications (INDs) with the FDA for
rh Factor XIII in late 2002 and for rhcombinant proteins,” said Charles E.
Hart, Senior Director of Corporate Thrombin in early 2003, paving the
way for Phase I clinical studies in pa-Communications and Investor Rela-
tions. “We see this as a real benefit tients.
Although the primary commer-as we advance our pipeline of prod-
uct candidates.” cialization strategy for ZymoGene-
tics is internal development andBut ZymoGenetics’ newfound in-
dependence has also provided the marketing, the company is also ag-
gressively leveraging its extensivecompany with the leeway to pursue
drug candidates with partners patent portfolio with various licens-
ing and partnership deals. Recentwhose focus and expertise better
matches the potential therapeutic examples include the establishment
of collaboration with Switzerland’sapplication at hand. Indeed, part of
the rational for the spin-off was Serono S.A. to develop TACI-Ig for
the treatment of autoimmune dis-borne out of the fact that many of
ZymoGenetics’ current and future ease. TACI is a cell surface receptor
that drives proliferation of B cells.product leads were unlikely to fit into
Novo’s strong focus on diabetes. Fusion of the extracellular domain of
receptor to a piece of an immuno-“Our bioinformatics-driven strategy
has allowed us to make discoveries globulin protein produces TACI-Ig—
effectively a decoy protein that sopsin many different therapeutic areas
rather than a single area of human up TACI’s natural ligand to prevent
aberrant receptor activation anddisease,” commented Carter. “Hav-
ing the flexibility to work with the B-cell proliferation that occurs in au-
toimmune disorders.appropriate partner for a given ther-
apeutic area will allow us to opti- Additionally, Novo Nordisk has
exercised options to license threemally advance our product candi-
dates into clinical trials and to the proteins discovered from ZymoGe-
netics’ bioinformatics activities. Themarket.”
As part of Novo, ZymoGenetics proteins are IL-21, a potential anti-
cancer drug, and IL-20 and its re-participated in the discovery or de-
velopment of five brand-name medi- ceptor, being studied for the treat-
ment of psoriasis. IL-21 is a cytokinecal products that together led to
sales in 2001 in excess of $2 billion. that appears to regulate levels of an-
tibody-producing B cells and alsoThese sales provided ZymoGenet-
ics with approximately $10 million in stimulates natural killer (NK) cells—
the immune system’s scavengerroyalties—a healthy income, but this
still left them $37 million in the red cells that roam the body in search of
cancerous prey. IL-20 is a cytokinein the last fiscal year. The key deter-
minant of ZymoGenetics’ ability to that acts on epidermal cells in the
skin. It has been implicated in thesurvive the next decade hinges on
the ability of the company’s discov- development of psoriasis in animal
models of the disease. Various otherery and development engine to bear
fruit in the form of marketable prod- proteins in preclinical development
are described on the ZymoGeneticsucts. The investors are optimistic.
ZymoGenetics pulled off its first website at www.zymogenetics.com.
Those following drug discoverypublic offering in the days following
September 11—hardly good timing. in the coming years will certainly be
paying attention to ZymoGenetics.Although they missed their price tar-
